Aditxt (ADTX)
Market Price (3/7/2026): $0.465 | Market Cap: $23,676Sector: Health Care | Industry: Biotechnology
Aditxt (ADTX)
Market Price (3/7/2026): $0.465Market Cap: $23,676Sector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Personalized Diagnostics, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -131%, 3Y Excs Rtn is -171% | Penny stockMkt Price is 0.5 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -345705% | ||
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 23029% | ||
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -97%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -60%, Rev Chg QQuarterly Revenue Change % is -89% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 8203% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -379978%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -379978% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 247% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -176512% | ||
| High stock price volatilityVol 12M is 10864% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 80% | ||
| Key risksADTX key risks include [1] severe financial instability raising substantial "going concern" doubts due to near-zero revenue and a large working capital deficit, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Personalized Diagnostics, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -131%, 3Y Excs Rtn is -171% |
| Penny stockMkt Price is 0.5 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -345705% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 23029% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -97%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -60%, Rev Chg QQuarterly Revenue Change % is -89% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 8203% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -379978%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -379978% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 247% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -176512% |
| High stock price volatilityVol 12M is 10864% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 80% |
| Key risksADTX key risks include [1] severe financial instability raising substantial "going concern" doubts due to near-zero revenue and a large working capital deficit, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Aditxt (ADTX) stock has lost about 90% since 11/30/2025 because of the following key factors:
1. Repeated Reverse Stock Splits and Persistent Nasdaq Delisting Threats.
Aditxt executed a 1-for-113 reverse stock split on January 11, 2026, following an earlier 1-for-113 reverse stock split effective November 3, 2025. These actions were primarily undertaken to regain and maintain compliance with Nasdaq's minimum bid price requirements. The company has faced ongoing delisting risks, having been notified in March 2025 of potential delisting due to its closing bid price falling below $0.10 for ten consecutive trading days.
2. Severe Deterioration in Financial Performance and "Going Concern" Doubts.
The company reported a net loss of $7.4 million for Q2 2025, contributing to a trailing twelve-month net loss of $36.9 million as of June 30, 2025. Revenue dramatically decreased to just $1,004 in Q2 2025, largely due to reduced demand for COVID testing. Aditxt's cash balance was notably low at $323,679 as of June 30, 2025, with a working capital deficit of $20.1 million and $5.7 million in accounts payable overdue by more than 90 days, leading management to disclose substantial doubt about the company's ability to continue as a going concern.
Show more
1. Repeated Reverse Stock Splits and Persistent Nasdaq Delisting Threats.
Aditxt executed a 1-for-113 reverse stock split on January 11, 2026, following an earlier 1-for-113 reverse stock split effective November 3, 2025. These actions were primarily undertaken to regain and maintain compliance with Nasdaq's minimum bid price requirements. The company has faced ongoing delisting risks, having been notified in March 2025 of potential delisting due to its closing bid price falling below $0.10 for ten consecutive trading days.
2. Severe Deterioration in Financial Performance and "Going Concern" Doubts.
The company reported a net loss of $7.4 million for Q2 2025, contributing to a trailing twelve-month net loss of $36.9 million as of June 30, 2025. Revenue dramatically decreased to just $1,004 in Q2 2025, largely due to reduced demand for COVID testing. Aditxt's cash balance was notably low at $323,679 as of June 30, 2025, with a working capital deficit of $20.1 million and $5.7 million in accounts payable overdue by more than 90 days, leading management to disclose substantial doubt about the company's ability to continue as a going concern.
Show more
Stock Movement Drivers
Fundamental Drivers
The -87.7% change in ADTX stock from 11/30/2025 to 3/6/2026 was primarily driven by a -87.7% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3062026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.80 | 0.47 | -87.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 32.5 | 4.0 | -87.7% |
| Shares Outstanding (Mil) | 0 | 0 | 0.0% |
| Cumulative Contribution | -87.7% |
Market Drivers
11/30/2025 to 3/6/2026| Return | Correlation | |
|---|---|---|
| ADTX | -87.7% | |
| Market (SPY) | -1.6% | -15.7% |
| Sector (XLV) | -3.1% | -16.0% |
Fundamental Drivers
The -99.6% change in ADTX stock from 8/31/2025 to 3/6/2026 was primarily driven by a -97.8% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3062026 | Change |
|---|---|---|---|
| Stock Price ($) | 116.39 | 0.47 | -99.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -50.7% |
| P/S Multiple | 179.6 | 4.0 | -97.8% |
| Shares Outstanding (Mil) | 0 | 0 | -63.5% |
| Cumulative Contribution | -99.6% |
Market Drivers
8/31/2025 to 3/6/2026| Return | Correlation | |
|---|---|---|
| ADTX | -99.6% | |
| Market (SPY) | 4.5% | 1.8% |
| Sector (XLV) | 11.6% | 0.5% |
Fundamental Drivers
The -100.0% change in ADTX stock from 2/28/2025 to 3/6/2026 was primarily driven by a -100.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3062026 | Change |
|---|---|---|---|
| Stock Price ($) | 1743.03 | 0.47 | -100.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -97.2% |
| P/S Multiple | 0.1 | 4.0 | 2595.8% |
| Shares Outstanding (Mil) | 0 | 0 | -100.0% |
| Cumulative Contribution | -100.0% |
Market Drivers
2/28/2025 to 3/6/2026| Return | Correlation | |
|---|---|---|
| ADTX | -100.0% | |
| Market (SPY) | 14.2% | 0.7% |
| Sector (XLV) | 3.9% | 0.7% |
Fundamental Drivers
The -100.0% change in ADTX stock from 2/28/2023 to 3/6/2026 was primarily driven by a -99.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282023 | 3062026 | Change |
|---|---|---|---|
| Stock Price ($) | 51076000.00 | 0.47 | -100.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -99.3% |
| P/S Multiple | � | 4.0 | 0.0% |
| Shares Outstanding (Mil) | � | 0 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/6/2026| Return | Correlation | |
|---|---|---|
| ADTX | -100.0% | |
| Market (SPY) | 76.0% | 0.5% |
| Sector (XLV) | 25.7% | 0.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ADTX Return | -74% | -96% | -86% | -100% | -100% | -48% | -100% |
| Peers Return | 16% | -31% | -27% | 2% | 40% | 11% | -6% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| ADTX Win Rate | 17% | 17% | 33% | 0% | 8% | 0% | |
| Peers Win Rate | 53% | 35% | 43% | 53% | 55% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| ADTX Max Drawdown | -74% | -96% | -93% | -100% | -100% | -48% | |
| Peers Max Drawdown | -14% | -47% | -42% | -28% | -23% | -8% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ADPT, VIR, ILMN, TMO, GILD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/6/2026 (YTD)
How Low Can It Go
| Event | ADTX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -100.0% | -25.4% |
| % Gain to Breakeven | 310224.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -77.6% | -33.9% |
| % Gain to Breakeven | 345.7% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
Compare to ADPT, VIR, ILMN, TMO, GILD
In The Past
Aditxt's stock fell -100.0% during the 2022 Inflation Shock from a high on 2/11/2021. A -100.0% loss requires a 310224.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Aditxt (ADTX)
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
AI Analysis | Feedback
Here are 1-3 brief analogies for Aditxt (ADTX):
- 23andMe for your immune system. (It provides personalized insights into your immune health.)
- CarFax for your immune system's health history. (It offers comprehensive reports and monitoring of your immune system's status over time.)
- Google Analytics for your immune system's health. (It provides a detailed 'dashboard' and insights into your immune system's performance and trends.)
AI Analysis | Feedback
- AditxtScore™: A personalized immune health monitoring platform that provides a comprehensive profile of an individual's immune system.
- AditxtExpress™: A network of clinical locations offering access to AditxtScore™ testing and other immune health services.
AI Analysis | Feedback
Aditxt (ADTX) primarily sells its diagnostic testing services and collaborates on research and development with other companies. According to its latest available SEC filings (Form 10-K for the fiscal year ended December 31, 2023), no single customer accounted for 10% or more of its total revenue. Therefore, Aditxt does not have individually named "major customers" that constitute a significant portion of its sales. Instead, the company serves various categories of businesses:
- Healthcare providers (e.g., hospitals, clinics, diagnostic laboratories)
- Clinical research organizations (CROs)
- Pharmaceutical companies
- Research institutions (e.g., universities, government research labs)
AI Analysis | Feedback
- Thermo Fisher Scientific, Inc. (Symbol: TMO)
- Agilent Technologies, Inc. (Symbol: A)
AI Analysis | Feedback
Amro Albanna Co-founder, Chairman, and Chief Executive Officer Mr. Albanna co-founded Aditxt in 2017 and has served as CEO since January 2017. He is described as an innovation entrepreneur with 25 years of experience launching and growing companies around promising technologies. Prior to Aditxt, he founded eight startups across various industries, including healthtech, nanotechnology, enterprise software, research incubation, GPS & wireless, nano sensors, consumer health, and e-commerce. Mr. Albanna has a history of exiting ventures through mergers and acquisitions and taking companies public on exchanges like the American Stock Exchange, NASDAQ, OTC, and Frankfurt Stock Exchange. Thomas J. Farley, CPA Chief Financial Officer Mr. Farley serves as the Chief Financial Officer of Aditxt. His background includes serving as the Controller and Treasurer of Business Development Corporation of America ("BDCA"), a publicly listed business development company, from December 2015 to June 2020. Before that, from January 2011 to August 2015, he was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Mr. Farley's experience also includes roles as a Senior Controller for PineBridge Investments Emerging Markets practice and an Accounting Manager for Bessemer Venture Partners. Shahrokh Shabahang, MS, PhD Co-founder, Chief Innovation Officer, Board Member Dr. Shabahang is a co-founder of Aditxt and serves as the Chief Innovation Officer and a Board Member. He brings over 20 years of experience in commercializing life science technologies. Corinne Pankovcin, CPA, MBA Chief Mergers & Acquisitions Officer Ms. Pankovcin is the Chief Mergers & Acquisitions Officer at Aditxt. She has a background that includes serving as Chief Financial Officer for several world-class organizations, including Business Development Corporation of America ("BDCA"), BlackRock Kelso Capital (NASDAQ BKCC), and AIG Capital Partners. In these roles, she was responsible for executing portfolio investments and managing significant M&A transactions. She also served as CFO of Aditxt since July 2020, effectively managing the company's growth as it became publicly traded on Nasdaq. Rowena Albanna Chief Operating Officer Ms. Albanna holds the position of Chief Operating Officer at Aditxt. She contributes over 20 years of leadership experience across the biotechnology, health innovation, and technology sectors.AI Analysis | Feedback
The key risks to Aditxt (ADTX) are primarily centered on its precarious financial stability, ongoing capital raising challenges leading to significant shareholder dilution, and inherent operational hurdles within the highly competitive biotechnology sector.
- Financial Instability and Going Concern Doubt: Aditxt faces severe financial strain, characterized by extremely low revenues (Q2 2025 sales were just $1,004 and trailing twelve-month revenue ending June 30, 2025, was only about $12.05 thousand, a 96.35% year-over-year decline) and substantial net losses (Q2 2025 net loss of $7.4 million, with a trailing twelve-month net loss hitting $36.9 million as of June 30, 2025). The company reported a net loss of $35,020,058 for the year ended December 31, 2024, and an accumulated deficit of $168,094,569. Furthermore, Aditxt has negative free cash flow of $11.7 million, a precarious cash balance of $323,679, and a working capital deficit of $20.1 million as of June 30, 2025. The company is significantly past due on vendor obligations, with approximately $5.7 million overdue by more than 90 days as of June 30, 2025, and $9.3 million over 90 days past due as of September 30, 2024, raising serious "going concern" questions. Aditxt also has negative shareholder equity of $-8.9M.
- Shareholder Dilution and Capital Raising Challenges: The company requires substantial additional capital to continue operations and fund clinical studies, which creates significant doubt about its ability to continue as a going concern. Aditxt has engaged in multiple securities purchase agreements to raise funds, but these efforts are expected to result in significant dilution for existing stockholders. The sale of shares under these agreements can cause the market price of the common stock to decline. In an effort to maintain its NASDAQ listing, the company executed a 1-for-113 reverse stock split effective November 3, 2025, reflecting a massive loss of investor confidence and significant prior shareholder dilution.
- Operational Challenges and Competitive Landscape: Aditxt has a limited operating history, which is common for early-stage companies but presents inherent uncertainties, risks, and difficulties. The biotechnology sector is fiercely competitive, with Aditxt competing against established pharmaceutical companies and well-funded biotech firms. The company also faces challenges in its acquisition strategy, such as the proposed acquisition of Cellvera being uncertain due to liquidation proceedings, which could impact its strategic plans. Additionally, the company relies on third parties for crucial research, preclinical studies, and clinical trials.
AI Analysis | Feedback
nullAI Analysis | Feedback
Aditxt (ADTX) operates in several addressable markets with its main products and services:
- AditxtScore™ for Immune Monitoring: The global immune response testing market was valued at USD 14 billion in 2024 and is anticipated to grow to USD 27.05 billion by 2033, with a CAGR of 7.6% from 2025 to 2033. The broader global immune monitoring solutions market is projected to grow at a CAGR of 12.9% from 2022 to 2027.
- AditxtScore™ for COVID-19: The global COVID-19 diagnostics market was estimated at USD 48.64 billion for 2022.
- Apoptotic DNA Immunotherapy (ADi™) / ADI-100 (for autoimmune diseases): The overall autoimmunity market is estimated at over USD 160 billion by 2030.
- Psoriasis Therapeutics (specific to ADI-100): The global psoriasis treatment market size was valued at USD 27.20 billion in 2024. It is projected to grow to USD 57.68 billion by 2032, exhibiting a CAGR of 10.2% during the forecast period. North America held a significant market share, valued at USD 20.32 billion in 2024. The U.S. psoriasis treatment market size is estimated at USD 10.10 billion in 2025 and is predicted to be worth around USD 20.53 billion by 2034.
- Type 1 Diabetes Therapeutics (specific to ADI-100): The global Type 1 Diabetes Treatment Market is projected to reach USD 14.3 billion by 2035, growing at a CAGR of 4.67% from 2025 to 2035. Another estimate places the global market at USD 16.97 billion in 2025, expected to reach USD 26.22 billion by 2032. The U.S. market accounted for 80.4% of global sales in 2023 (USD 2.2 billion) and is expected to reach USD 9.0 billion by 2033. North America held the largest revenue share in the global Type 1 diabetes market in 2024, accounting for 45.7%.
- Apoptotic DNA Immunotherapy (ADi™) / ADI-100 (for transplanted organ rejection): The global organ and tissue transplantation and alternatives market is projected to reach USD 120.3 billion by 2024.
- Pearsanta™ (Precision Diagnostics):
- Endometriosis Diagnostics: A global market of USD 1.45 billion.
- Prostate Cancer Diagnostics: The global prostate cancer diagnostics market size was estimated at USD 7,726.8 million in 2023 and is projected to reach USD 11,894.4 million by 2030, growing at a CAGR of 6.4% from 2024 to 2030. In 2024, North America dominated this market with a 46% share. The U.S. prostate cancer diagnostics market size was USD 3.15 billion in 2024 and is projected to be around USD 5.97 billion by 2034.
- NeuroCap and NeuroEEG (EEG brain monitoring technologies): The global electroencephalography (EEG) devices market size was approximately USD 1.67 billion in 2024 and is predicted to grow to around USD 5.26 billion by 2034, with a CAGR of 11.1% from 2025 to 2034. The U.S. held a significant share of the North American market in 2023.
- NeuroCap and NeuroEEG (Tele-neurology/Digital Health in Neurology): The global digital health in neurology market was estimated at USD 39.82 billion in 2024 and is predicted to surpass around USD 303.23 billion by 2034, expanding at a CAGR of 22.51% from 2025 to 2034. North America held the largest market share of 38% in 2024. The U.S. digital health in neurology market size was USD 13.32 billion in 2024 and is projected to be worth around USD 103.32 billion by 2034.
AI Analysis | Feedback
Aditxt (ADTX) anticipates several key drivers for future revenue growth over the next 2-3 years, primarily centered around its innovative biotechnology pipeline and strategic market initiatives:
- Product Innovations in Immune System Health: Aditxt is focused on developing and commercializing technologies aimed at improving the health of the immune system. This includes the advancement of its proprietary AditxtScore platform and Adimune's therapeutic programs, which are undergoing preclinical studies for conditions such as psoriasis, diabetes, and Stiff Person Syndrome. These innovations aim to prevent immune system attacks, addressing the root causes of these conditions.
- Expansion of Diagnostic Capabilities through Pearsanta: The company is expanding its diagnostic capabilities through its subsidiary, Pearsanta. A significant driver is the development of a blood-based diagnostic test for endometriosis, which has begun its first human study. Pearsanta is also preparing for a potential initial public offering (IPO), leveraging its focus on breakthroughs in cancer detection.
- Strategic Collaborations, Licensing, Acquisitions, and Partnerships: Aditxt's revenue trajectory is expected to be influenced by strategic collaborations, licensing agreements, acquisitions, and partnerships. The company is actively pursuing these external growth strategies to broaden its market reach and enhance its product offerings.
- Market Expansion: Aditxt is evaluating opportunities to expand its presence within existing markets and penetrate new geographical areas, aiming to broaden the reach of its technologies and services.
AI Analysis | Feedback
Share Issuance
- Aditxt completed its initial public offering in June 2020, pricing 1,226,668 units at $9.00 per unit, raising approximately $11.0 million. Each unit included one share of common stock and two types of warrants.
- The company has implemented multiple reverse stock splits, including a 1-for-250 reverse split effective March 17, 2025, and a 1-for-113 reverse split effective November 3, 2025, primarily to maintain compliance with Nasdaq's minimum bid price requirement.
- In July 2024, Aditxt secured $500,000 in cash proceeds from an accredited investor through the issuance of a senior note and a warrant to purchase up to 1,250,000 shares of common stock. Additionally, the company raised nearly a million dollars through senior notes and an additional $4.2 million in a private placement.
Inbound Investments
- In July 2024, Aditxt received $500,000 in cash proceeds as part of a strategic financing agreement with an accredited investor, involving a senior note and warrants.
- As part of its merger strategy with Evofem Biosciences, Aditxt made equity investments, including an adjusted third investment of $720,000 and a fourth of $2.28 million. Additionally, in April 2025, Aditxt invested $1.5 million in Evofem in exchange for a convertible note and a warrant.
Outbound Investments
- Aditxt has pursued an M&A strategy, notably acquiring Appili Therapeutics in April 2024, although the arrangement agreement was later terminated in May 2025.
- The company is in the process of merging with Evofem Biosciences, which was acquired in December 2023.
- Aditxt completed the acquisition of Pearsanta in early 2024, and had also acquired AiPharma in December and October 2021.
Capital Expenditures
- Aditxt's reported capital expenditures have been in the range of N/A, -$14 thousand, -$367 thousand, -$1,016 thousand, and -$171 thousand in various periods.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ADTX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 69.74 |
| Mkt Cap | 10.6 |
| Rev LTM | 2,310 |
| Op Inc LTM | 398 |
| FCF LTM | 454 |
| FCF 3Y Avg | 311 |
| CFO LTM | 528 |
| CFO 3Y Avg | 389 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.2% |
| Rev Chg 3Y Avg | -1.0% |
| Rev Chg Q | 6.1% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Mgn LTM | -1.2% |
| Op Mgn 3Y Avg | -33.2% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 0.5% |
| CFO/Rev 3Y Avg | -17.8% |
| FCF/Rev LTM | -1.8% |
| FCF/Rev 3Y Avg | -21.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 10.6 |
| P/S | 5.2 |
| P/EBIT | 8.0 |
| P/E | 10.5 |
| P/CFO | 8.8 |
| Total Yield | 0.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -4.6% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -9.2% |
| 3M Rtn | -1.3% |
| 6M Rtn | 20.8% |
| 12M Rtn | 22.9% |
| 3Y Rtn | -23.1% |
| 1M Excs Rtn | -7.1% |
| 3M Excs Rtn | -6.3% |
| 6M Excs Rtn | 17.2% |
| 12M Excs Rtn | 6.8% |
| 3Y Excs Rtn | -91.3% |
Price Behavior
Price Behavior
| Market Price | $0.47 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 06/30/2020 | |
| Distance from 52W High | -100.0% | |
| 50 Days | 200 Days | |
| DMA Price | $0.77 | $68.82 |
| DMA Trend | down | down |
| Distance from DMA | -39.8% | -99.3% |
| 3M | 1YR | |
| Volatility | 176.1% | 10,886.0% |
| Downside Capture | 520.61 | 586.41 |
| Upside Capture | -615.53 | -322.07 |
| Correlation (SPY) | -14.6% | 0.7% |
ADTX Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.96 | -1.18 | -2.22 | 22.67 | 3.43 | 1.87 |
| Up Beta | 4.90 | 5.95 | 2.42 | -378.09 | -42.15 | -23.72 |
| Down Beta | -0.93 | -9.32 | -11.03 | -0.59 | 0.46 | 2.12 |
| Up Capture | -259% | -237% | -364% | -197% | -56% | -7% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 5 | 13 | 20 | 40 | 86 | 269 |
| Down Capture | 585% | 362% | 492% | 363% | 176% | 113% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 16 | 27 | 40 | 82 | 158 | 460 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ADTX | |
|---|---|---|---|---|
| ADTX | -100.0% | 10,864.5% | 0.93 | - |
| Sector ETF (XLV) | 3.4% | 17.5% | 0.04 | 0.7% |
| Equity (SPY) | 16.4% | 19.2% | 0.66 | 0.6% |
| Gold (GLD) | 77.1% | 26.1% | 2.17 | 0.0% |
| Commodities (DBC) | 19.6% | 17.1% | 0.89 | 4.1% |
| Real Estate (VNQ) | 3.1% | 16.6% | 0.01 | -1.0% |
| Bitcoin (BTCUSD) | -21.4% | 45.5% | -0.39 | -5.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ADTX | |
|---|---|---|---|---|
| ADTX | -99.1% | 4,864.3% | 0.38 | - |
| Sector ETF (XLV) | 7.6% | 14.5% | 0.34 | 0.2% |
| Equity (SPY) | 13.0% | 17.0% | 0.60 | 0.5% |
| Gold (GLD) | 24.2% | 17.2% | 1.14 | 0.4% |
| Commodities (DBC) | 11.9% | 19.0% | 0.51 | 1.8% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | -0.4% |
| Bitcoin (BTCUSD) | 7.5% | 56.8% | 0.35 | -2.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ADTX | |
|---|---|---|---|---|
| ADTX | -90.9% | 4,571.1% | 0.36 | - |
| Sector ETF (XLV) | 10.4% | 16.5% | 0.52 | 0.2% |
| Equity (SPY) | 15.0% | 17.9% | 0.72 | 0.5% |
| Gold (GLD) | 15.1% | 15.6% | 0.80 | 0.4% |
| Commodities (DBC) | 9.0% | 17.6% | 0.43 | 1.8% |
| Real Estate (VNQ) | 6.1% | 20.7% | 0.26 | -0.4% |
| Bitcoin (BTCUSD) | 66.7% | 66.8% | 1.06 | -2.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/13/2020 | -1.0% | -1.0% | 3.0% |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 1 |
| # Negative | 1 | 1 | 0 |
| Median Positive | 3.0% | ||
| Median Negative | -1.0% | -1.0% | |
| Max Positive | 3.0% | ||
| Max Negative | -1.0% | -1.0% | |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/18/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/18/2024 | 10-Q |
| 06/30/2024 | 08/19/2024 | 10-Q |
| 03/31/2024 | 05/20/2024 | 10-Q |
| 12/31/2023 | 04/16/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 04/17/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.